CD274 and non-small cell lung carcinoma: Trastuzumab-modified mannosylated liposomes and PD-L1-modified liposomes, both designed to deliver gefitinib, demonstrated strong anti-tumor effects and good safety profiles in NSCLC mouse models with T790M mutation.